Synthetic lethality, where combining two non-lethal mutations results in cell death, is exploited in cancer therapy, with PARP inhibitors like olaparib targeting BRCA-deficient cells by exploiting this interaction.  Werner syndrome helicase (WRN) is a synthetic lethal target in cancers with microsatellite instability due to impaired DNA mismatch repair.  WRN is synthetically lethal with MLH1, a …Read More >

Polycythemia vera (PV) is a chronic myeloproliferative disorder, a type of blood cancer characterized by the overproduction of red blood cells (erythrocytosis) which can lead to thicker blood and an increased risk of blood clot.  Most cases of PV are caused by a point mutation in the JAK2 gene (JAK2-V617F). To support drug discovery teams …Read More >

Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) are globally prevalent human pathogens associated with a wide range of diseases, from mild conditions such as herpes labialis (cold sores) to serious infections such as encephalitis and meningitis. HSV can establish a lifelong latent infection in neurons of the peripheral nervous system and can reactivate …Read More >

Epilepsy is a chronic brain disorder characterized by recurring seizures, which are episodes of uncontrolled and abnormal electrical activity in the brain that can cause changes in behavior, sensations, awareness, and movement.  Epilepsy has a wide range of consequences, impacting neurobiology, cognition, and psychosocial well-being. To support drug discovery teams focused on epilepsy research, our …Read More >

Rare neurological diseases are conditions affecting the nervous system that occur infrequently, with examples including Huntington’s disease, Rett syndrome, and Amyotrophic Lateral Sclerosis (ALS). These rare disorders can be classified into various categories based on the affected systems/organs, among which, neuroinflammatory & neuroimmunology-related disorders, movement disorders, and motor neuron disease show higher prevalence. To support …Read More >

Indoleamine 2,3-dioxygenase 1 (IDO1) is an enzyme that metabolizes tryptophan, and its activity can lead to immunosuppression, thereby allowing tumors to evade the immune system. IDO1 can also suppress the immune response through mechanisms independent of its enzyme activity, and this may be difficult to target with current inhibitors.  Drugs targeting only IDO1 enzyme activity …Read More >

Despite the excellent clinical response to paclitaxel therapy, drug resistance inevitably develops in subsequent treatments. The development of targeted therapies for overcoming paclitaxel resistance represents an unmet medical need. Although not fully understood, the mechanisms for resistance to paclitaxel include drug efflux transporter overexpression, altered apoptotic gene expression, and changes associated with microtubules to reduce …Read More >

Asthma is a chronic, lower airway disease characterized by persistent inflammation and hyperreactivity. Asthma involves a complex immune response, with T-helper 2 (Th2) cells playing a central role, leading to activation of eosinophils and increased levels of IgE antibodies. Clinically, airflow obstruction in asthma often is not fully reversible, and many asthmatic subjects experience an …Read More >

Approximately 20-40% of diffuse large B-cell lymphoma (DLBCL) patients experience relapsed or refractory disease after initial treatment with R-CHOP (a combination therapy regimen for DLBCL that combines chemotherapy drugs with rituximab). Polatuzumab vedotin is an antibody-drug conjugate (ADC) used to treat DLBCL, both in first-line treatment and for relapsed or refractory cases. At the 2025 …Read More >